Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033437 | 0.80 | MCHR1 (0.48) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL9810196 | 0.79 | MCHR1 (0.52) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL13746013 | 0.79 | NCF1 (0.42) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL7970266 | 0.77 | MCHR1 (0.50) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL3771034 | 0.77 | NOS3 (0.54) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL15544743 | 0.77 | NOS2 (0.54) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL26151328 | 0.77 | MCHR1 (0.46) | MCHR1 | |
| SCHEMBL6690974 | 0.76 | CRHBP (0.41) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL1256181 | 0.76 | MCHR1 (0.40) | MCHR1NCF1KMT2AMAPTKDM4E | |
| SCHEMBL20679536 | 0.76 | NCF1 (0.40) | MCHR1NCF1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106496139-A | The synthetic method of 4,6 dimethoxypyridin of medical raw material, 5 amine | 无锡乾浩生物医药有限公司 | 2017-03-15 | — | — | CN | claimed |
| EP-3604305-B1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| EP-4063358-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-111615388-B | Immunotherapeutic agent for cancer | 斯汀格瑞治疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023160672-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO , INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11713299-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010022308-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
| EP-1943241-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1943234-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| CN-101107259-A | Silicon compounds and their use | TAKEDA CAMBRIDGE LTD (GB) | 2008-01-16 | — | — | CN | disclosed |
| WO-2007051981-A1 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007051982-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | MCHR1 2767/4885NCF1 396/4885KMT2A 4450/4885 |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | STING1, IRF3, CGAS | MCHR1 786/4885NCF1 524/4885KMT2A 2485/4885 |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | MCHR1 4104/4885NCF1 965/4885KMT2A 3024/4885 |
| US-11713299-B2 | Histone methyltransferase inhibitors | EHMT1, DOT1L, EHMT2 | MCHR1 2230/4885NCF1 3253/4885KMT2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.